The company is starting off with the development and delivery of daxibotulinumtoxinA, Revance’s highly purified botulinum toxin type A, and the first neuromodulator with long-acting duration.

Revance aims to become a global leader in both aesthetic medicine and underserved therapeutic specialties such as dermatology, neurology, and musculoskeletal disorders.